en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Guide › Compound Identity And Development History — Research Overview

Compound Identity And Development History — Research Overview

By Editorial Desk · published 2025-11-20 · last reviewed 2025-12-18 · Guide

A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Analytical Characterization and Storage

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

Background and Molecular Features

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Related pages on this site

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.

Supporting material

Throughout Belize's history, Guatemala has claimed sovereignty over all or part of Belizean territory. This claim is occasionally reflected in maps drawn by Guatemala's government, showing Belize as Guatemala's twenty-third department. The Guatemalan territorial claim involves approximately 53% of Belize's mainland, which includes significant portions of four districts: Belize, Cayo, Stann Creek, and Toledo. Roughly 43% of the country's population (≈154,949 Belizeans) reside in this region. As of 2020, the border dispute with Guatemala remains unresolved and contentious. Guatemala's claim to Belizean territory rests, in part, on Clause VII of the Anglo-Guatemalan Treaty of 1859, which obligated the British to build a road between Belize City and Guatemala. At various times, the issue has required mediation by the United Kingdom, Caribbean Community heads of government, the Organization of American States (OAS), Mexico, and the United States. In April 2018, Guatemala's government held a referendum to determine if the country should take its territorial claim on Belize to the International Court of Justice (ICJ) to settle the long-standing issue. Guatemalans voted 95% yes on the matter. A similar referendum was to be held in Belize in April 2019, but a court ruling led to its postponement. The referendum was held in May 2019, and 55.4% of voters opted to send the matter to the ICJ. Both countries submitted requests to the ICJ (in 2018 and 2019, respectively) and the ICJ ordered Guatemala's initial brief be submitted by December 2020 and Belize's response by 2022.

This mosaicity allows for substantial shedding of tumor cells into the vasculature, possibly contributing to the appearance of circulating tumor cells in the peripheral blood of patients with malignancies. The subsequent growth of such metastases will also require a supply of nutrients and oxygen and a waste disposal pathway. Endothelial cells have long been considered genetically more stable than cancer cells. This genomic stability confers an advantage to targeting endothelial cells using anti-angiogenic therapy, compared to chemotherapy directed at cancer cells, which rapidly mutate and acquire drug resistance to treatment. Thus, endothelial cells are thought to be an ideal target for therapies against cancer.. Currently, there have been multiple clinical trials using anti-angiogenic therapies in combination with other therapeutic agents (e.g chemotherapy for treatment of various cancers.

==== Chlorophylls ==== Chlorophyll a is found in all chloroplasts, as well as their cyanobacterial ancestors. Chlorophyll a is a blue-green pigment partially responsible for giving most cyanobacteria and chloroplasts their color. Other forms of chlorophyll exist, such as the accessory pigments chlorophyll b, chlorophyll c, chlorophyll d, and chlorophyll f. Chlorophyll b is an olive green pigment found only in the chloroplasts of plants, green algae, any secondary chloroplasts obtained through the secondary endosymbiosis of a green alga, and a few cyanobacteria. It is the chlorophylls a and b together that make most plant and green algal chloroplasts green. Chlorophyll c is mainly found in secondary endosymbiotic chloroplasts that originated from a red alga, although it is not found in chloroplasts of red algae themselves. Chlorophyll c is also found in some green algae and cyanobacteria. Chlorophylls d and f are pigments found only in some cyanobacteria.

Sources: en.wikipedia.org

Supporting material

=== United States === According to Trump, the US would "run" Venezuela until there is a "safe, proper and judicious transition". Trump went on to say that the US and US companies would seize Venezuelan oil and sell it to other countries. Trump said the US would be "very strongly involved" in the Venezuelan oil industry, and that US oil companies would invest billions of dollars in the energy sector of the country. Secretary of Defense Pete Hegseth said "We are going to get American companies in there" to invest in the Venezuelan oil industry, resulting in "access to additional wealth and resources" for the US. The government also indicated that American oil companies would have to invest in rebuilding Venezuelan oil infrastructure as a prerequisite for being compensated for previous asset seizures by the Venezuelan government since the first nationalization nearly 50 years ago. Vice President JD Vance stated that the operation was justified as Maduro was wanted in the US. He also declared that "the stolen oil must be returned". Chairwoman Lisa McClain of the House Republican Conference called Maduro a "narcoterrorist" and said that "Trump didn't look the other way; he acted." After initially expressing uncertainty about the justification of US actions, Republican senator Mike Lee later said they "likely" fell under the president's Article II powers to protect against "actual or imminent attack". Florida Senators Rick Scott and Ashley Moody, along with Representative Carlos Gimenez, held a press conference in Doral praising the capture of Maduro.

==== Synthesis ==== Fluorescent nanoparticles are highly sought after. They have broad applications, but their use in macroscopic arrays allows them efficient in applications of plasmonics, photonics, and quantum communications. While there are many methods in assembling nanoparticles array, especially gold nanoparticles, they tend to be weakly bonded to their substrate so they can't be used for wet chemistry processing steps or lithography. Nanodiamonds allow for greater variability in access that can subsequently be used to couple plasmonic waveguides to realize quantum plasmonic circuitry.

==== Cough ==== Codeine was once viewed as the "gold standard" in cough suppressants, but this position has since been questioned. Some recent placebo-controlled trials have found that it may be no better than a placebo for some causes including acute cough in children. As a consequence, it is not recommended for children. Additionally, there is no evidence that hydrocodone is useful in children. Similarly, a 2012 Dutch guideline regarding the treatment of acute cough does not recommend its use. Low dose morphine may help chronic cough but its use is limited by side effects.

=== Analogues === A notable analogue of SDMA is 4T-MMDA-2 (2-methoxy-4T-MDA), which was described by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved). Other analogues of SDMA include SDA, MDMA, 5-MAPB, and 6-MAPBT, among others.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

How is sample identity confirmed?

Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.

Network